Literature DB >> 30023455

Exercise training as S-Klotho protein stimulator in sedentary healthy adults: Rationale, design, and methodology.

Francisco J Amaro-Gahete1,2, Alejandro De-la-O1, Lucas Jurado-Fasoli1, Andrea Espuch-Oliver3, Lidia Robles-Gonzalez1, Ginés Navarro-Lomas1, Tomás de Haro4, Pedro Femia5, Manuel J Castillo1, Angel Gutierrez1.   

Abstract

AIMS: The secreted form of the α-Klotho gene (S-Klotho), which is considered a powerful biomarker of longevity, makes it an attractive target as an anti-ageing therapy against functional decline, sarcopenic obesity, metabolic and cardiovascular diseases, osteoporosis, and neurodegenerative disorders. The S-Klotho plasma levels could be related to physical exercise inasmuch physical exercise is involved in physiological pathways that regulate the S-Klotho plasma levels. FIT-AGEING will determine the effect of different training modalities on the S-Klotho plasma levels (primary outcome) in sedentary healthy adults. FIT-AGEING will also investigate the physiological consequences of activating the klotho gene (secondary outcomes).
METHODS: FIT-AGEING will recruit 80 sedentary, healthy adults (50% women) aged 45-65 years old. Eligible participants will be randomly assigned to a non-exercise group, i.e. the control group, (n = 20), a physical activity recommendation from World Health Organization group (n = 20), a high intensity interval training group (n = 20), and a whole-body electromyostimulation group (n = 20). The laboratory measurements will be taken at the baseline and 12 weeks later including the S-Klotho plasma levels, physical fitness (cardiorespiratory fitness, muscular strength), body composition, basal metabolic rate, heart rate variability, maximal fat oxidation, health blood biomarkers, free-living physical activity, sleep habits, reaction time, cognitive variables, and health-related questionnaires. We will also obtain dietary habits data and cardiovascular disease risk factors.

Entities:  

Year:  2018        PMID: 30023455      PMCID: PMC6022251          DOI: 10.1016/j.conctc.2018.05.013

Source DB:  PubMed          Journal:  Contemp Clin Trials Commun        ISSN: 2451-8654


Introduction

The global elderly population will dramatically increase by 2050 [1]. Despite the current rise in life expectancy, the increases in disease-free years are higher, concentrating the prevalence of chronic diseases in old age [2]. Age-related diseases, such as cardiovascular diseases, osteoporosis, cancer and neurodegenerative disorders, represent the major cause of morbidity and mortality in developed countries, with an exponential growth of health costs [3,4]. However, significant inter-individual variability exists in the health impact of ageing [5]. Therefore, it is necessary to find strategies which can attenuate the ageing process and improve the quality of life [6]. The α-Klotho gene encodes a type I single-pass transmembrane protein of 1014 amino acid long, and it expresses itself in three functionally different family members: the intra-cellular form which binds sodium-potassium adenosine triphosphatase, the cell-membrane form which forms a complex with fibroblast growth factor 23 and fibroblast growth factor receptor 1 and the secreted form (S-Klotho), identified in blood, plasma, urine, and cerebrospinal fluid [7]. The S-Klotho is considered a powerful biomarker of longevity [8] and has several anti-ageing functions such as regulating the metabolism of calcium and phosphate metabolism [avoiding cell's precipitation of calcium phosphate and reducing apoptosis mechanism [[8], [9], [10], [11]]], reducing the inflammatory process [12] and the oxidative stress [13], and protecting the oxidative stress cells, obtaining an anti-ageing effect derived from these actions. Recent findings have discovered a pool of novel α-Klotho gene activators such as Na+-dependent Pi cotransporter type IIa (NaPi-IIa) and Na+-dependent Pi cotransporter type IIb (NaPi-IIb) [[9], [10], [11]], insulin, insulin-like growth factor-1 (IGF-1), transforming growth factor beta (TGF-β), Wnt signaling pathway, and interferon gamma (IFNγ) [14,15], and fibroblast growth factor 21 (FGF21) [16]. Physical fitness, which includes cardiorespiratory fitness [17,18] and muscular strength [19], is an excellent predictor of both cardiovascular and all-cause mortality [20]. In addition, it is an important predictor of living independently at older ages in both men and women [21]. Moreover, it is well known that exercise improves physical fitness in healthy [22] and unhealthy people [23], and it may also be effective in preventing, delaying, or reversing the ageing effects on tissue health and functioning [24]. Of interest is that several studies have reported that exercise induces the activation of various factors that also increase the expression of the α-Klotho gene [25,26]. Several studies have shown that a single bout of exercise produces an S-Klotho plasma levels increase both in animal models [27] and in humans [28,29]. Although Matsubara el al. (2014) showed that aerobic exercise training increased the S-Klotho plasma levels in postmenopausal women [30], little is known about which are the chronic effects of different training modalities on the S-Klotho plasma levels in sedentary healthy adults. The overall objective and primary outcome of the FIT-AGEING randomized controlled trial (RCT) is to quantify the effects of different training modalities on the S-Klotho plasma levels in sedentary healthy adults. The training modalities will be (i) no exercise, (ii) physical activity recommendation from the World Health Organization, (iii) High Intensity Interval Training, and (iv) Whole-Body Electromyostimulation training. The secondary outcomes of this study will focus on the quantification of the effects of the above-mentioned training modalities on physical fitness components, body composition and anthropometric measurements, energy expenditure and nutrients oxidation, heart rate variability (HRV), health blood biomarkers, free-living physical activity, cognitive variables, health-related quality of life, dietary habits, and cardiovascular disease risk factors.

Methods

The present study is a RCT (ClinicalTrials.gov ID: NCT03334357) approved by The Human Research Ethics Committee of the “Junta de Andalucia” [0838-N-2017]. All participants will have to provide an informed consent. The participants will be randomly allocated to a control group, a physical activity recommendation group (PAR), high intensity interval training group (HIIT), and whole-body electromyostimulation group (WB-EMS). All of the baseline and follow-up examinations will be performed at the same setting [Instituto Mixto Universitario Deporte y Salud (IMUDS) at the University of Granada]. The study will follow the revised ethical guidelines of the Declaration of Helsinki.

Participants and selection criteria

The participants will be adults from the province of Granada (Spain). Granada has ≈885,000 population, of which ≈190,000 are adults aged 45–65. The eligible participants should be 45–65 years old, and they must have a body mass index (BMI) between 18.5 and 35 kg/m2. The inclusion and exclusion criteria are listed in Table 1. We decided to conduct the intervention on overweight and obese adults because overweight and obesity accelerate the ageing of adipose tissue, increase the formation of reactive oxygen species in fat cells, shorten telomeres, and produce the inhibition of the p53 tumor suppressor [31], which are factors that could be related to the S-Klotho plasma levels. Considering that aerobic exercise is able to increase the S-Klotho plasma levels in normal-weight young and senior adults according to literature [32], we will also include participants with a BMI between 18.5 and 24.9 kg/m2. Including people with different weight status and body composition allows to study S-Klotho plasma levels differences across different categories (i.e. normal-weight, overweight, and obese based on BMI, and on body fat measures).
Table 1

Selection criteria.

Inclusion criteriaExclusion criteria
Age: 45–65 years oldHistory of cardiovascular disease
Body mass index: 18.5–35 kg/m2Diabetes
Not engaged in regular physical activity >20min on >3 day/weekPregnancy or planning to get pregnant during the study period
Not participating in a weight-loss programBeta blockers or benzodiazepines use
Stable weight over the last 5 months (body weight changes>5 kg)Taking medication for thyroid
The participants must be capable and willing to provide consent, understand the exclusion criteria, and accept the randomized group assignmentOther significant conditions that are life-threatening or that can interfere with or be aggravated by exercise
Normal electrocardiogramUnwillingness to either complete the study requirements or to be randomized into the control or training group
Selection criteria. All participants will have a health history and a medical examination done prior to the intervention program to minimize risks by ruling out contraindications to the testing and training protocols. If any participant suffers any injury or medical problem, a medical evaluation will be performed and, if necessary, they will be excluded from the study. The study will be announced on social networks, local media, and posters at different points of Granada. We will also organize information meetings at the School of Medicine of the University of Granada. The people interested will be able to contact the research team by e-mail and phone. Later, they will visit our facilities to receive a thorough explanation about the study's aims, the test to be performed, the inclusion and exclusion criteria, and the types of intervention. What participants can expect from the study will be clarified, and any questions will be answered. The potentially interested participants meeting the inclusion criteria will be invited to a second orientation session; in this case, the participants will receive detailed written information about the study, and the informed consent. The participants will be cited for their baseline measurement. Fig. 1 shows the participant flow from the recruitment to the randomization stages.
Fig. 1

Flow diagram of the study participants.

Flow diagram of the study participants. After completing the baseline measurements, the selected participants will be randomly assigned to either the control or the exercise training groups. The randomization will be computer-generated. We will use simple randomization [33], hence disparities in group size and in the number of men and women are possible. The assessment staff will be blinded to the participant randomization assignment. The participants will be explicitly informed of their assigned group, as well as of the study hypotheses. They will also be frequently reminded not to disclose their randomization assignments to the assessment staff in the follow-up measurements. For practical and feasibility reasons, the study will be conducted in two waves (maximum 45 participants).

Sample size

The determination of the sample size and power of the study are made based on the data of a pilot S-Klotho plasma levels sample [34]. We have considered S-Klotho plasma levels differences between pre and post-treatment in order to assess the sample size requirements for the one-way ANOVA [35]. As a result, we expect to detect an effect size of 100 pg/ml considering a type I error of 0.05 with a statistical power of 0.85 if we consider a minimum of 14 participants per group. Assuming a maximum loss at follow-up of 25%, we decided to recruit 20 participants (≈50% women) for each study group: control, PAR, HIIT, and WB-EMS. A total of 80 participants (≈40 women and ≈40 men) will be enrolled in FIT-AGEING. Based on previous RCT and on our own experience [36,37], we think that the sample size is realistic and accessible.

Statistical analysis

All outcome variables will be verified for normality, and the results will be expressed as mean and SD. For between group comparisons at the baseline (control group vs PAR vs HIIT vs WB-EMS), we will analyze continuous variables with the one-way analysis of variance or the non-parametric method of Kruskal–Wallis and Chi-square tests, as appropriate. We will use General Lineal Models to assess the training effects [time (pre-post 3-month intervention) × group interactions] on the primary and secondary study outcomes. We will adjust multiple comparisons for mass significance [38]. We will also examine the differences in the baseline measurements between the participants who remain in the study and the drop-outs. We will analyze the data according to the intention-to-treat principle [39], and we will handle missing data resulting from drop-outs or non-compliance using multiple imputation methods. To fully appreciate the potential influence of missing responses, we will perform sensitivity analyses to examine whether the imputation method affects the outcomes. In addition, we will perform multiple regression analyses to evaluate potential independent predictors of the α-Klotho protein concentration.

Participant retention and adherence

The participants will be allowed to withdraw at any time; however, to reduce participants drop-out and to maintain adherence to the training program, several strategies will be implemented. In anticipation of private commitments, vacations, etc., the intervention program will be carried out from September to December. All sessions will be accompanied by music, and will be held on an airy, well-lighted, and well-equipped gym. Qualified and certificated trainers will carefully supervise every training session, and they will work with groups of no more than three persons to ensure that the participants will do the exercises correctly, and at a correct intensity. The training specialist and other study staff will constantly support the participants.

Exercise program rationale

Since there is no information regarding the ideal exercise model to induce higher levels of the S-Klotho plasma levels, FIT-AGEING will apply different exercise methods. These methods will be (i) PAR [[40], [41], [42], [43]], (ii) HIIT, and (iii) WB-EMS. One of the most important aims of the study is to compare various exercise intensity levels (moderate vs. high intensity) to test if higher intensity levels provide more benefits despite the application of a lower training volume. The trial length will be twelve weeks based on (i) the results of a previous study [30] and (ii) taking into account that the substantial physiological adaptations occur within the first 3–6 months of exercise [40]. We will provide no dietary prescriptions or instructions to the participants in the control and exercise groups. The participants will be asked to maintain their dietary habits during the intervention period.

PAR training

Volume

Given the importance of the transferability of results to the general population in terms of time, intensity, and frequency, the volume of PAR will be based on the minimum physical activity recommended by the World Health Organization (150 min/week at moderate intensity).

Intensity

Physical activity at moderate intensity is recommended to sedentary people by important health institutions to obtain health benefits [41,42,44]. Physical activity at 60% of the heart rate reserve produces significant physiological adaptations in sedentary adults [41,42,44]. For this reason, the intensity selected for PAR aerobic training is 60–65% of the heart rate reserve (HRres). One-repetition maximum (1RM) is the maximum amount of force that can be generated in one maximal contraction, and it is used to determine the intensity of resistance training [45]. The World Health Organization recommends an intensity of 40–50% of 1RM to improve muscle strength, and to increase muscle mass in sedentary persons which have never done strength training [43]. Therefore, the intensity selected for this training modality is 40–50% of 1RM. We will also consider other variables that influence strength training, such as eccentric-isometric-concentric speed ratio, recovery time, and range of motion [46].

Frequency

Considering several studies that have compared the effects of different training frequencies on physical fitness as a health marker, the World Health Organization recommends a dose of 3 or 4 days/week [44]. Because the lack of time is one of the most important causes of participant dropout, we have determined that the PAR group will train 3 days/week, the minimum frequency recommended. Resistance training will be performed on 2 of these 3 days/week. In addition, the participants will be advised to refrain from training for a minimum of 24 h and ideally 48 h. The participants will be phoned if they do not meet the weekly recommendations.

Type of exercise

The exercises programmed for the aerobic training section will be treadmill, cycle-ergometer, and elliptical ergometer. For the resistance training section, we will include weight-bearing and guided pneumatic machines, involving the major upper and lower body muscle groups [43].

Training load variation

We consider that participants may not be immediately capable of meeting the volume and intensity dose required. Therefore, we have proposed a gradual progression to control the exercise dose (see Table 2) based on a previous RCT [37].
Table 2

PAR training periodization.

PHASESWEEKSAEROBIC TRAINING
RESISTANCE TRAINING
Volume (min)Intensity (%HRres)Intensity (%RM)Type of exerciseTraining stimulus
FAMILIARIZATIONWEEK 17560Weight-bearing and elastic bandMovement pattern and global movementsMovement patternCompensatory training
WEEK 210560
PHASE IWEEK 312060RM ASSESTMENT
WEEK 41506050Exercises involving major muscle groupsInitial adaptations to resistance trainingCompensatory training
WEEK 51506050
WEEK 61506050
WEEK 71506050
PHASE IIWEEK 812060RM ASSESTMENT
WEEK 91506050Exercises involving major muscle groupsSession type A: mechanical tension and muscle damageSession type B:Metabolic Stress
WEEK 101506050
WEEK 111506050
WEEK 121506050

PAR: Physical Activity Recommendations for adults proposed by the World Health Organization, HRres: Heart Rate Reserve, RM: Repetition Maximum.

PAR training periodization. PAR: Physical Activity Recommendations for adults proposed by the World Health Organization, HRres: Heart Rate Reserve, RM: Repetition Maximum. The participants will begin with an aerobic dose of 75 min/week at 60%HRres. It will progressive increase 30 min/week, and the participants will achieve 150 min/week on the 4th week. Regarding resistance training, the participants will perform a 2-week familiarization phase; they will learn the movement patterns which are based on resistance exercises of a specific training program (dead lift, squat, horizontal, and vertical push-pull, etc.). In addition, the participants will do compensatory exercises to improve core competency and joints stabilization, in order to avoid injuries. It is well known that, as the fitness level of participants increases, aerobic and strength load should be higher. Aerobic training intensity will increase, since it is necessary to rise the previously established intensity to maintain a specific percentage of HRres, when the physical fitness is increased. In addition, we will measure the RM of all exercises on the first week of each phase in order to adjust the resistance training load. On the other hand, it is important to consider that the session organization determines different physiological adaptations in terms of muscle hypertrophy (metabolic stress, muscle damage etc.) [46]. Due to the fact that the best training stimulus to induce higher levels of the S-Klotho plasma levels is unknown, we will include different types of sessions during each training phase.

Training periodization

The training periodization is shown in Table 2. It is divided into two different phases, and its duration will be of 5 weeks, starting with a familiarization phase. The training program structure is based on other randomized controlled trials, which had the aim to meet the physical activity recommendations for adults suggested by World Health Organization [37,41]. FAMILIARIZATION PHASE: This phase will last two weeks. The principal aim of this phase will be to learn the main movement patterns (squat, hinge, bridge, and horizontal and vertical pulls and push) and to improve many physical fitness components such as cardiorespiratory fitness, core stability, joint stabilizing muscles, balance, and flexibility. These sessions will prepare the participants for the 1RM evaluation. PHASE 1: The participants will perform two combined sessions (aerobic and resistance training) and only one aerobic training session in phase 1. The aerobic training volume will be 150 min/week (except in RM weeks, with a duration of 120 min/week) and the aerobic training intensity will be 60%HRres in all cases. The resistance training will include exercises involving the major muscle groups and principal movement patterns (squat, bench press, dead lift, lateral pull down …) and compensatory exercises. Combined sessions will have type I structure (see Table 3) which alternate 4 resistance exercises involving the major muscle groups, 2 core stability exercises, and 2 compensatory exercises with 10-min sets of aerobic training.
Table 3

Combined training session in the PAR training program.

Session Type I
Session Type II
EXERCISESETSVOLUMEINTENSITYEXERCISESETSVOLUMEINTENSITY
WARM-UP
WARM-UP
Aerobic Warm-up15 min60% HRresAerobic Warm-up15 min60% HRres
Dynamic Warm-up
1
5 min

Dynamic Warm-up
1
5 min

MAIN PART
MAIN PART
Aerobic I110 min60% HRresAerobic I110 min60% HRres
Resistance Exercise I110 reps40–50% RMAerobic II110 min60% HRres
Resistance Exercise II110 reps40–50% RMResistance Exercise I110 reps40–50% RM
Resistance Exercise III110 reps40–50% RMResistance Exercise V110 reps40–50% RM
Resistance Exercise IV110 reps40–50% RMResistance Exercise II110 reps40–50% RM
Aerobic II110 min60% HRresResistance Exercise VI110 reps40–50% RM
Resistance Exercise I110 reps40–50% RMResistance Exercise III110 reps40–50% RM
Resistance Exercise II110 reps40–50% RMResistance Exercise VI110 reps40–50% RM
Resistance Exercise III110 reps40–50% RMResistance Exercise IV110 reps40–50% RM
Resistance Exercise IV110 reps40–50% RMResistance Exercise VIII110 reps40–50% RM
Aerobic III110 min60% HRresAerobic III110 min60% HRres
Resistance Exercise I110 reps40–50% RMAerobic IV110 min60% HRres
Resistance Exercise II110 reps40–50% RMCOOL-DOWN15 min
Resistance Exercise III110 reps40–50% RM
Resistance Exercise IV110 reps40–50% RM
Aerobic IV110 min60% HRres
Resistance Exercise I110 reps40–50% RM
Resistance Exercise II110 reps40–50% RM
Resistance Exercise III110 reps40–50% RM
Resistance Exercise IV110 reps40–50% RM
COOL-DOWN15 min

PAR: Physical Activity Recommendations for adults proposed by the World Health Organization, HRres: Heart Rate Reserve, RM: Repetition Maximum, Reps: Repetitions, Min: minutes.

Combined training session in the PAR training program. PAR: Physical Activity Recommendations for adults proposed by the World Health Organization, HRres: Heart Rate Reserve, RM: Repetition Maximum, Reps: Repetitions, Min: minutes. PHASE 2: In this case, the combined sessions will be different in order to provide a different resistance training stimulus [41,46,47]. The combined session will be divided into type I session (which focuses on mechanical tension and muscle damage) and type II session (which focuses on metabolic stress) [46,47]. Both sessions will include similar exercises to those reported in phase 1, as well as several exercises which involve small muscle groups (lateral raises, French press, or lateral raises).

Training sessions

The participants should complete a total of 60 min of aerobic exercise in non-combined sessions (only aerobic exercises). These sessions will start with a dynamic standardized warm-up, including several muscle activation exercises. In addition, aerobic sessions will include compensatory exercises. All combined training sessions will begin like a non-combined session. After the warm-up, an aerobic exercise will be carried out on 10-min sets, alternating with resistance exercises (depending on the session [see Table 3]). The participants will have the possibility to change the ergometer in different 10-min aerobic sets (treadmill, elliptical, or cycle-ergometer). In all cases, the training session will end with a cooling-down protocol (active global stretching); the participants will complete 5 anterior or posterior chain exercises.

HIIT training

HIIT describes physical exercise characterized by short and intermittent efforts of vigorous activity, interspersed with resting periods at passive or low-intensity exercises. There are many HIIT protocols, and the specific physiological adaptations induced by this training modality are related to exercise stimulus, (i.e. the intensity, duration, or number of intervals performed), as well as the duration and activity patterns during recovery [48,49]. The energy expenditure at HIIT (more intensity and low volume) is the same (or even higher in some cases) as moderate intensity exercise. However, HIIT physiological and health-related markers are better in healthy and diseased populations [[49], [50], [51]]. These findings are important from a public health perspective, because the ‘lack of time’ is one of the most common problems to do exercise. The volume in HIIT (40–65 min/week at high intensity) will be smaller than the minimum physical activity recommended by the World Health Organization (75 min/week at vigorous intensity). The HIIT intensity is based on scientific evidence [48,49,52,53]. HIIT participants will perform two different complementary protocols: (i) HIIT with long intervals (Type A session), with an intensity of >95% maximum oxygen uptake (VO2max) and (ii) HIIT with short intervals (Type B session), with an intensity of >120% VO2max (>90% HRres or <9 Rating of Perceived Exertion {0–10 RPE scale} [54]). The intensity will progressively increase after the familiarization phase. Traditionally, HIIT has been recommended 3 times/week [52,53]. However, considering the age of the participants (45–65 years old) and their training level (sedentary), we have decided to reduce the training frequency (twice per week), since this population needs a 72-h rest after a HIIT session [55]. The exercises programmed for HIIT with long intervals (type A session) are walking on the treadmill with personalized slopes. For the HIIT with short intervals (type B session), the participants will perform eight weight-bearing exercises in circuit form, (i.e. squat, dead lift, high knees up, high heels up, push up, horizontal row, lateral plank, and frontal plank). We consider that participants will not be immediately capable of meeting the volume and intensity dose required; therefore, we propose a gradual progression to control the exercise dose. The participant will start with a dose of <40 min/week at 80%–90% VO2max in type A and type B sessions (HIIT familiarization phase). It will progressive increase to 50 min/week at >95% in type A session and 120% VO2 max in type B session (HIIT phase I) and to 65 min/week at >95% in type A session and 120% VO2 max in type B session (HIIT phase II). The training periodization is shown in Table 4. It is divided into three phases: (1) HIIT familiarization phase, (2) HIIT phase I, (3) HIIT phase II.
Table 4

HIIT training periodization.

HIIT Familiarization phase
Week1234
Session (type)1 (A)2 (B)3 (A)4 (B)5 (A)6 (B)7 (A)8 (B)
Exercises1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)
Volume12 min16 min14 min21 min16 min16 min18 min21 min
Intensity80%VO2m80%VO2m80%VO2m80%VO2m90%VO2m90%VO2m90%VO2m90%VO2m
Sets62728292
Set duration4 min8 min4 min10.5 min4 min8 min4 min10.5 min
Work exercise2 min15 Sec2 min20 Sec2 min15 Sec2 min20 Sec
Rest exercise2 min (pass)15 Sec2 min (pass)20 Sec2 min (pass)15 Sec2 min (pass)20 Sec
Rest between sets

5 min (60% VO2m)

5 min (60% VO2m)

5 min (60% VO2m)

5 min (60% VO2m)
HIIT PHASE I
Week5678
Session (type)9 (A)10 (B)11 (A)12 (B)13 (A)14 (B)15 (A)16 (B)
Exercises1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)
Volume16 min16 min18 min21 min20 min27 min20 min32 min
Intensity>95% VO2m120%VO2m>95%VO2m120%VO2m>95%VO2m120%VO2m>95%VO2m120%VO2m
Sets8292102102
Set duration4 min8 min4 min10.5 min4 min13.5 min4 min16 min
Work exercise2 min15 Sec2 min20 Sec2 min25 Sec2 min30 Sec
Rest exercise2 min (pass)15 Sec2 min (pass)20 Sec2 min (pass)25 Sec2 min (pass)30 Sec
Rest between sets

5 min (60% VO2m)

5 min (60% VO2m)

5 min (60% VO2m)

5 min (60% VO2m)
HIIT PHASE II
Week9101112
Session (type)17 (A)18 (B)19 (A)20 (B)21 (A)22 (B)23 (A)24 (B)
Exercises1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)1 (Tr)8 × 2 = 16 (W-B)
Volume18 min24 min21 min31.5 min24 min40.5 min24 min40.5 min
Intensity>95%VO2m120%VO2m>95%VO2m120%VO2m>95%VO2m120%VO2m>95%VO2m120%VO2m
Sets63738383
Set duration4 min8 min4 min10.5 min4 min13.5 min4 min13.5 min
Work exercise3 min15 Sec3 min20 Sec3 min25 Sec3 min25 Sec
Rest exercise2 min (pass)15 Sec2 min (pass)20 Sec2 min (pass)25 Sec2 min (pass)25 Sec
Rest between sets5 min (60% VO2m)5 min (60% VO2m)5 min (60% VO2m)5 min (60% VO2m)

Type A; High Intensity Interval Training on the treadmill with individual slopes, Type B; High Intensity Interval Power Training (weight-bearing exercises), Tr; Treadmill, W-B; Weight-Bearing exercises, VO2m; Maximum oxygen uptake, Min; minutes, Sec; seconds, Pas; Passive.

HIIT training periodization. Type A; High Intensity Interval Training on the treadmill with individual slopes, Type B; High Intensity Interval Power Training (weight-bearing exercises), Tr; Treadmill, W-B; Weight-Bearing exercises, VO2m; Maximum oxygen uptake, Min; minutes, Sec; seconds, Pas; Passive. HIIT FAMILIARIZATION PHASE: This phase will last 4 weeks. The participants will carry out 2 types of sessions each week, type A and type B. The intensity selected for the first and the second week will be 80% VO2max. The intensity and the volume will be higher in the third and fourth week. In session type A, the participants will complete 6–9 sets of 4 min (2 min work/2 min rest) with a maximal duration of 18 min/session. In session type B, the participants will complete 2 sets (8–9.5 min) of 16 exercises (15–20 s work/15–20 s rest) with an active rest of 5 min at 60% VO2max and a maximal duration of 19 min/session. HIIT PHASE I: The participants will do two different sessions as in the familiarization phase. The intensity will be >95%VO2max in type A session, and >120%VO2max in type B session. The training volume will be less than 50 min/week. In session type A, the participants will complete 8–10 sets of 4 min (2 min work/2 min rest) with a maximal duration of 20 min/session. In session type B, the participants will complete 2 sets (8–12.5 min of duration) of 16 exercises (15–30 s work/15–30 s rest) with an active rest of 5 min at 60% VO2max and a maximal duration of 25 min/session. HIIT PHASE II: Sessions will follow the same structure than HIIT PHASE I. However, training volume will be more than 50 min/week but less than 65 min/week. In session type A, the participants will complete 6–8 sets of 5 min (3 min work/2 min rest) with a maximal duration of 24 min/session (intensity >95% VO2max). In session type B, the participants will complete 3 sets (8–12.5 min duration) of 16 exercises (15–30 s work/15–30 s rest) with an active rest of 5 min–60% VO2max and a maximal duration of 37 min/session (intensity >120% VO2max). The exercises in session type B can be modified in order to increase their difficulty (add external load, increase range of motion, add instability, etc.) because it will be expected that physical fitness increases as a training adaptation. Type A session: It will start with a dynamic standardized warm-up, including several muscle activation exercises followed by 5 min of aerobic exercise on the treadmill at 60% VO2max. After the warm-up, the participants will complete several treadmill sets following the established parameters previously described. Type B session: It will start with a dynamic standardized warm-up. The participants will perform eight weight-bearing exercises (in circuit form) twice per set with an active rest (walking at 60%VO2max) following the periodization previously established. In all cases, the training session will end with the same cooling-down protocol described in PAR.

WB-EMS training

WB-EMS is becoming increasingly popular as a novel training technology. WB-EMS is able to simultaneously stimulate up to 14–18 regions or 8–12 different muscle groups with up to 2.800 cm2 electrode area [56]. Very few studies have determined the influence of WB-EMS on ageing, physical fitness, body composition, and physiological parameters in sedentary healthy adults [[57], [58], [59]], and its effects are controversial [60,61]. Therefore, it is essential to follow the scientific recommendations related to WB-EMS to avoid possible health problems [62,63] produced by the irresponsible use of this technology [58,59,63]. The WB-EMS training program will follow the same structure as the HIIT intervention in terms of volume, intensity, frequency, type of exercise, training load variation, training periodization, and training session. However, electrical impulses will be included in order to assess whether the WB-EMS training will produce an extra effect compared with the HIIT program.

Electrical parameters

Given that the participants have never done WB-EMS, we decided to establish a progressive and gradual WB-EMS training periodization in order to avoid possible dangerous health consequences, such as increased creatine kinase levels and rhabdomyolysis [60,61]. The electrical parameters progression is shown in Table 5. Using the WB-EMS devices from Wiemspro® (Malaga, Spain), bipolar, symmetrical, and rectangular electric pulse will be applied. The periodization of electric parameters can be seen in Table 5.
Table 5

Electrical parameters in the WB-EMS training periodization.

FAMILIARIZATION PHASE
Week1234
Session (type)1 (A)2 (B)3 (A)4 (B)5 (A)6 (B)7 (A)8 (B)
Frequency15 Hz35 Hz15 Hz35 Hz15 Hz40 Hz15 Hz40 Hz
Intensity100 mA80 mA100 mA80 mA100 mA80 mA100 mA80 mA
RPE impulse (0–10)5–65–66–76–77–87–87–87–8
Duty cycle
99% (59¨:1¨)
50% (15¨:15¨)
99% (59¨:1¨)
57% (20¨:15¨)
99% (59¨:1¨)
50% (15¨:15¨)
99% (59¨:1¨)
57% (20¨:15¨)
HIIT PHASE I
Week5678
Session (type)9 (A)10 (B)11 (A)12 (B)13 (A)14 (B)15 (A)16 (B)
Frequency20 Hz45 Hz20 Hz45 Hz20 Hz50 Hz20 Hz55 Hz
Intensity100 mA80 mA100 mA80 mA100 mA80 mA100 mA80 mA
RPE impulse (0–10)7–87–87–87–87–87–87–87–8
Duty cycle
99% (59¨:1¨)
50% (15¨:15¨)
99% (59¨:1¨)
57% (20¨:15¨)
99% (59¨:1¨)
63% (25¨:15¨)
99% (59¨:1¨)
67% (30¨:15¨)
HIIT PHASE II
Week9101112
Session (type)17 (A)18 (B)19 (A)20 (B)21 (A)22 (B)23 (A)24 (B)
Frequency25 Hz60 Hz20 Hz65 Hz20 Hz70 Hz20 Hz75 Hz
Intensity100 mA80 mA100 mA80 mA100 mA80 mA100 mA80 mA
RPE impulse (0–10)8–98–98–98–98–98–98–98–9
Duty cycle99% (59¨:1¨)50% (15¨:15¨)99% (59¨:1¨)57% (20¨:15¨)99% (59¨:1¨)63% (25¨:15¨)99% (59¨:1¨)63% (25¨:15¨)

Type A; High Intensity Interval Training on the treadmill with individual slopes, Type B; High Intensity Interval Power Training (weight-bearing exercises), Hz; Hertz, mA; milliamps.

Electrical parameters in the WB-EMS training periodization. Type A; High Intensity Interval Training on the treadmill with individual slopes, Type B; High Intensity Interval Power Training (weight-bearing exercises), Hz; Hertz, mA; milliamps. The typical frequency used in WB-EMS studies has been 85 Hz [[56], [57], [58], [59],63]. However, our participants will be sedentary adults aged 45–65, and it has been shown that ageing is associated with a muscle mass decrease, especially type II fibers, and this decrease in muscle tissue begins around the age of 50 and dramatically increases beyond the age of 60 [64,65]. In addition, it is well-known that the ideal frequency to recruit type I fibers is 7–33 Hz [66]. Therefore, we will apply a frequency of 15–33 Hz in our type A session (aerobic exercise). On the other hand, we will apply a frequency of 35–75 Hz in the type B session (resistance exercises) because, in this case, it will be active type II fibers and the optimal frequency is 35–100 Hz [66]. INTENSITY: The intensity applied in our intervention program will be 80–100 mA, following the scientific guidelines established in local electrostimulation in order to improve fitness and body composition (>50 mA) [66]. The impulse intensity was individually adapted in accordance with the participants in order to generate similar values of rate of perceived exertion (RPE) than other WB-EMS studies (49, 54–59) using the Borg CR-10 Scale “5” of “9” [67]. IMPULSE WIDTH: The scientific recommendations regarding this matter range between 200 and 400 μsec. We adjusted this parameter in relation to the body segment: thigh zone (400 μsec), glute zone (350 μsec), abdominal zone (300 μsec), dorsal zone (250 μsec), cervical (200 μsec), chest zone (200 μsec), and arm zone (200 μsec) [66]. DUTY CYCLE: The stimulation ratio (duty cycle) is defined as ratio of on-time to the total cycle time (% duty cycle = 100/[total time/on-time]). A duty cycle of 50–70% will be used [[57], [58], [59],68]. We have programmed a duty cycle of 50–67% in type B (resistance training) session following scientific evidence, but duty cycle in type A session (aerobic exercise) will be 99% because the frequency will be low and the work time will be of 3 min maximum.

Control group

We will provide general advice to the control group participants though an information meeting presided by a graduate in Sport Sciences. They will be instructed to maintain their lifestyle.

Outcome variables

The primary outcome of our study is the S-Klotho plasma levels. The secondary outcome variables include physical fitness components, body composition and anthropometric measurements, energy expenditure and nutrients oxidation, heart rate variability (HRV), health blood biomarkers, free-living physical activity, cognitive variables, health-related quality of life, dietary habits, and cardiovascular disease risk factors (secondary outcomes) in sedentary healthy adults. The baseline measurement will be organized on 4 days: Day 1: Medical examination (anamnesis, blood pressure assessment …) and fasting blood measurements. Day 2: HRV during 15 min, basal metabolic rate measure by indirect calorimetry during 30 min, body composition by Dual Energy X-ray Absorptiometry scan (DXA) and anthropometric measurements, and maximal fat oxidation during an incremental treadmill protocol with a gas analyzer. All tests will be conducted under fasting conditions. Day 3: Isokinetic dynamometry strength test, cognition test and a questionnaire battery test which includes the ALPHA – Questionnaire Environment Perception, the Beck Depression Inventory (BDI-II), the Sedentary Behavior, the Physical Activity Attitude Questionnaire (C-AAF), Par-Q & You, the Health Questionnaire SF-36, the Socio-demographic data, the HOPE assessment, the Physical Fitness Condition Scale-International (IFIS), the Pittsburgh Sleep quality, the Revised Life Orientation Test (LOTR), the Satisfaction With Life Scale (SWLS), the Trait-Meta Mood Scale (TMMS-24), the Positive and Negative Affect Schedule (PANAS), PREDIMED questionnaire, and the Sexual Desire Questionnaire. Day 4: Muscle strength test (manual isometric dynamometry and core resistance stability), simple and discriminative reaction test and maximum exercise test on a treadmill (h/p cosmos, Italy) with a gas analyzer, electrocardiogram, and blood pressure control. All tests will be supervised by a graduate in sport sciences, and a sport medicine doctor. We will use accelerometers to objectively measure physical activity, sleep quality, and sleep volume. Finally, we will control the dietary intake by three 24 h recalls and by a food frequency questionnaire.

Primary outcome: S-Klotho plasma levels

We will collect blood samples from the antecubital vein after 12 h of fasting. The S-Klotho plasma levels will be measured by ELISA using a soluble α-klotho ELISA assay kit (Demeditec, Kiel, Germany). The kit is a non-competitive solid-phase sandwich ELISA that uses two types of highly specific antibodies (purified mouse anti-human Klotho IgG). The optical density is measured at a wavelength of 450 nm ± 2 nm and a standard curve is generated using known antigen concentrations. All participants will be requested to abstain from drugs and/or caffeine, to eat a standardized dinner before sampling, and to avoid any physical activity of moderate intensity (24 h before) and/or vigorous intensity (48 h before). We will also measure ageing markers such as a general biochemical profile, red cells profile, immunological blood profile, brain-derived neurotrophic factor, IGF-1, insulin, growth hormone, testosterone, free-testosterone, cortisol, dehydroepiandrosterone, and D hormone. The ELISA kits and spectrophotometry will be utilized to perform these analyses.

Secondary outcome

Physical fitness

Cardiorespiratory fitness will be measured through a maximum treadmill test (h/p cosmos, Italy) applying the modified Balke protocol [69], which has been widely used and validated [37,[70], [71], [72]]. We will also measure the O2 uptake and CO2 production with the breath by breath gas analyzer (CPX Ultima CardiO2, Medical Graphics Corp, St Paul, USA) calibrated with known gas mixtures and environmental air immediately before the test. Consistently across each trial, the participants will be strongly encouraged to invest maximum effort. The criteria for achieving VO2max will be respiratory exchange ratio ≥1.1, a plateau in VO2 (change of <100 ml/min in the last three consecutive 10 s stage), and a heart rate within 10 beats/min of the age-predicted maximal heart rate (208–0.7∗age) [73]. We will include a second and constant work rate test performed at 110% of the work rate achieved after the modified Balke protocol test to resolve the classic V̇O2-work rate plateau, which is the unambiguous validation of VO2max [74]. The exercise electrocardiogram will be continuously monitored. We will conduct isokinetic strength tests using a Gymnex Iso-2 dynamometer (EASYTECH s.r.l., Italy), calibrated following the product instructions before the data collection. The knee extensor muscles will be tested concentrically and eccentrically at 180° and 60° s-1. The upper members, hips, and shoulders will be stabilized with safety belts. The rotational axis of the dynamometer will be aligned with the right lateral femoral condyle. The force pad will be placed 3–4 cm above the medial malleolus. The knee extension will start with a 90º-joint angle and it will end at 170°. The subject will be instructed to sub maximally flex and extend the knee five times, and then complete three maximal repetitions. We will allow the participants a 1-min rest between submaximal and maximal trials, and 5 min between 180° and 60° s-1, following a scientific validated protocol [75]. The peak torque will be determined as the single repetition with the highest muscular force output (Nm). The participants will be encouraged by the trainer during the test, and the same trainer-researcher will conduct all the isokinetic testings. We will measure the handgrip strength using a digital dynamometer (TKK 5101 Grip-D; Takey, Tokyo, Japan). It will be measured following the procedures described elsewhere [76]. We will evaluate the core resistance stability using a standard protocol described by McGill et al. [77], which has been extensively used in scientific studies [78,79]. This methodology includes the Biering-Sorensen extensor endurance test, flexor endurance test (60°), frontal plank test, and the side bridge test.

Body composition and anthropometric measurements

The body weight, height, hip circumference, and waist circumference will be determined following the recommended standardization procedures from the International Society for the Advancement of Kinanthropometry (ISAK). We will also evaluate the fat mass, fat free mass, lean body mass, visceral adipose tissue, and bone mineral density by conducting a DXA scan (HOLOGIC, Wi).

Energy expenditure and nutrients oxidation

We will evaluate the basal metabolic rate by indirect calorimetry with a breath by breath gas analyzer (CPX Ultima CardiO2, Medical Graphics Corp, St Paul, USA). The participants will be requested to attend the center in the post-absorptive condition (12–14 h fasting), abstain from drugs and/or caffeine, eat an established dinner before sampling, avoid physical activity of moderate intensity (24 h before) and/or vigorous intensity (48 h before). They will lie down on a bed, in a quiet environment. Calorimetric measures will follow the scientific accepted standard to ensure the validity of the tests [80,81]. A standardized treadmill protocol test will be used to measure maximal fat oxidation [82]. More specifically, the test will start at 3.5 km h−1 and at a gradient of 0% during 3 min. The speed will then increase until reaching the maximal speed that the participant can comfortably maintain without running. The grade will increase by 2% every 3 min until a respiratory quotient of 1 is reached. After that, the speed will decrease until 4 km*h −1, and the grade will be 0% during 5 min (active recovery). The respiratory gas measurements will continuously be collected using a metabolic cart (CPX Ultima CardiO2, Medical Graphics Corp, St Paul, USA). Furthermore, the heart rate and rating of the perceived exertion (RPE) record will be measured throughout the whole test.

Heart rate variability (HRV)

The assessment of HRV will be carried out in a supine position before the basal metabolic rate test. Polar RS800CX (Polar Electro, Kempele, Finland) will be used to evaluate this parameter (R-R series active). The participants will be informed that their heart activity will be recorded during 10 min, and they will be instructed not to talk or move excessively, and to relax as much as possible. The participants will be in a supine position during 5 min prior to the start of the recording. We will use the Kubios HRV software (University of Eastern Finland, Kuopio, Finland) to process the HRV [83].

Physical activity

The amount of physical activity and sleep will be measured by accelerometry (ActiSleep, Actigraph, Pensacola, Florida, USA). The participants will wear two accelerometers (non-dominant wrist and right hip) during 7 consecutive days for 24 h to assess physical activity volume and intensity and sleep quantity and quality.

Cognitive performance and reaction time

Cognitive deterioration is one of the most apprehensive aspects of ageing, and it has been shown that exercise contributes to maintaining cognitive and brain function [84]. We will evaluate cognitive functions through simple and discriminative reaction time (Vienna Test System, Moedling, Austria) and the Wechsler Adult Intelligence Scale test battery (WAIS-III), which has been applied in several scientific studies [85].

Dietary assessment

We will conduct a dietary assessment at the baseline and after the intervention. Three 24-h dietary recalls (1 during the weekend). We will also administer the participants a food frequency questionnaire. All data will be processed by the dietetic software EVALFINUT® (Ibero-American Foundation of Nutrition, Spain).

Potential impact of FIT-AGEING

‘Health, demographic change, and wellbeing’ is one of the main challenges of Horizon 2020. FIT-AGEING contributes to the improvement of our understanding of the causes and mechanisms underlying health, healthy ageing, and disease, which is the principal topic that Research & Innovation has supported (€2 billion). Previous studies have shown that health disabilities (diabetes, osteoporosis, sarcopenic obesity, etc.) could be attributed exclusively to age [[86], [87], [88]]. The expression of the α-Klotho gene is positively correlated with a longer life spam, and the lack of the α-Klotho gene expression is related to ageing phenotypes such as artheriosclerosis, decreased bone mineral density, sarcopenia, skin atrophy, and impaired cognition [89]. Similar anti-ageing effects have also been ascribed to exercise and physical activity [20]. Therefore, the α-Klotho and physical activity are factors that may promote upgrading capacities of the elderly and their relation has been shown in scientific studies [32]. However, the mechanism that may mediate these effects is currently unknown. FIT-AGEING will study the effect of different exercise modalities on the S-Klotho plasma levels during 3 months (our principal outcome) for the first time in humans. In addition, FIT-AGEING will also measure other important health-related variables that may be related to the ageing process. Our study integrates physiology, biochemical parameters, and preventive medicine in order to investigate how physical exercise can induce an increase of the S-Klotho plasma levels in adults. The findings from FIT-AGEING could be significant implications for our understanding of exercise and its protective effects against the ageing process and ageing-related diseases.
  75 in total

Review 1.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

Review 2.  Electromyostimulation--a systematic review of the influence of training regimens and stimulation parameters on effectiveness in electromyostimulation training of selected strength parameters.

Authors:  Andre Filipovic; Heinz Kleinöder; Ulrike Dörmann; Joachim Mester
Journal:  J Strength Cond Res       Date:  2011-11       Impact factor: 3.775

3.  Effects of whole-body electromyostimulation on resting metabolic rate, body composition, and maximum strength in postmenopausal women: the Training and ElectroStimulation Trial.

Authors:  Wolfgang Kemmler; Rebecca Schliffka; Jerry L Mayhew; Simon von Stengel
Journal:  J Strength Cond Res       Date:  2010-07       Impact factor: 3.775

Review 4.  Best practice methods to apply to measurement of resting metabolic rate in adults: a systematic review.

Authors:  Charlene Compher; David Frankenfield; Nancy Keim; Lori Roth-Yousey
Journal:  J Am Diet Assoc       Date:  2006-06

5.  Does core stability exercise improve lumbopelvic stability (through endurance tests) more than general exercise in chronic low back pain? A quasi-randomized controlled trial.

Authors:  Mohammad Bagher Shamsi; Mandana Rezaei; Mehdi Zamanlou; Mehdi Sadeghi; Mohammad Reza Pourahmadi
Journal:  Physiother Theory Pract       Date:  2016-02-11       Impact factor: 2.279

6.  Regulation of autophagy in human skeletal muscle: effects of exercise, exercise training and insulin stimulation.

Authors:  Andreas M Fritzen; Agnete B Madsen; Maximilian Kleinert; Jonas T Treebak; Anne-Marie Lundsgaard; Thomas E Jensen; Erik A Richter; Jørgen Wojtaszewski; Bente Kiens; Christian Frøsig
Journal:  J Physiol       Date:  2016-01-15       Impact factor: 5.182

Review 7.  Mortality trends in the general population: the importance of cardiorespiratory fitness.

Authors:  Duck-chul Lee; Enrique G Artero; Xuemei Sui; Steven N Blair
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

8.  Influence of Whole-Body Electrostimulation on Human Red Blood Cell Deformability.

Authors:  Andre Filipovic; Heinz Kleinöder; Denise Plück; Wildor Hollmann; Wilhelm Bloch; Marijke Grau
Journal:  J Strength Cond Res       Date:  2015-09       Impact factor: 3.775

9.  Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

Authors:  Christopher J L Murray; Ryan M Barber; Kyle J Foreman; Ayse Abbasoglu Ozgoren; Foad Abd-Allah; Semaw F Abera; Victor Aboyans; Jerry P Abraham; Ibrahim Abubakar; Laith J Abu-Raddad; Niveen M Abu-Rmeileh; Tom Achoki; Ilana N Ackerman; Zanfina Ademi; Arsène K Adou; José C Adsuar; Ashkan Afshin; Emilie E Agardh; Sayed Saidul Alam; Deena Alasfoor; Mohammed I Albittar; Miguel A Alegretti; Zewdie A Alemu; Rafael Alfonso-Cristancho; Samia Alhabib; Raghib Ali; François Alla; Peter Allebeck; Mohammad A Almazroa; Ubai Alsharif; Elena Alvarez; Nelson Alvis-Guzman; Azmeraw T Amare; Emmanuel A Ameh; Heresh Amini; Walid Ammar; H Ross Anderson; Benjamin O Anderson; Carl Abelardo T Antonio; Palwasha Anwari; Johan Arnlöv; Valentina S Arsic Arsenijevic; Al Artaman; Rana J Asghar; Reza Assadi; Lydia S Atkins; Marco A Avila; Baffour Awuah; Victoria F Bachman; Alaa Badawi; Maria C Bahit; Kalpana Balakrishnan; Amitava Banerjee; Suzanne L Barker-Collo; Simon Barquera; Lars Barregard; Lope H Barrero; Arindam Basu; Sanjay Basu; Mohammed O Basulaiman; Justin Beardsley; Neeraj Bedi; Ettore Beghi; Tolesa Bekele; Michelle L Bell; Corina Benjet; Derrick A Bennett; Isabela M Bensenor; Habib Benzian; Eduardo Bernabé; Amelia Bertozzi-Villa; Tariku J Beyene; Neeraj Bhala; Ashish Bhalla; Zulfiqar A Bhutta; Kelly Bienhoff; Boris Bikbov; Stan Biryukov; Jed D Blore; Christopher D Blosser; Fiona M Blyth; Megan A Bohensky; Ian W Bolliger; Berrak Bora Başara; Natan M Bornstein; Dipan Bose; Soufiane Boufous; Rupert R A Bourne; Lindsay N Boyers; Michael Brainin; Carol E Brayne; Alexandra Brazinova; Nicholas J K Breitborde; Hermann Brenner; Adam D Briggs; Peter M Brooks; Jonathan C Brown; Traolach S Brugha; Rachelle Buchbinder; Geoffrey C Buckle; Christine M Budke; Anne Bulchis; Andrew G Bulloch; Ismael R Campos-Nonato; Hélène Carabin; Jonathan R Carapetis; Rosario Cárdenas; David O Carpenter; Valeria Caso; Carlos A Castañeda-Orjuela; Ruben E Castro; Ferrán Catalá-López; Fiorella Cavalleri; Alanur Çavlin; Vineet K Chadha; Jung-Chen Chang; Fiona J Charlson; Honglei Chen; Wanqing Chen; Peggy P Chiang; Odgerel Chimed-Ochir; Rajiv Chowdhury; Hanne Christensen; Costas A Christophi; Massimo Cirillo; Matthew M Coates; Luc E Coffeng; Megan S Coggeshall; Valentina Colistro; Samantha M Colquhoun; Graham S Cooke; Cyrus Cooper; Leslie T Cooper; Luis M Coppola; Monica Cortinovis; Michael H Criqui; John A Crump; Lucia Cuevas-Nasu; Hadi Danawi; Lalit Dandona; Rakhi Dandona; Emily Dansereau; Paul I Dargan; Gail Davey; Adrian Davis; Dragos V Davitoiu; Anand Dayama; Diego De Leo; Louisa Degenhardt; Borja Del Pozo-Cruz; Robert P Dellavalle; Kebede Deribe; Sarah Derrett; Don C Des Jarlais; Muluken Dessalegn; Samath D Dharmaratne; Mukesh K Dherani; Cesar Diaz-Torné; Daniel Dicker; Eric L Ding; Klara Dokova; E Ray Dorsey; Tim R Driscoll; Leilei Duan; Herbert C Duber; Beth E Ebel; Karen M Edmond; Yousef M Elshrek; Matthias Endres; Sergey P Ermakov; Holly E Erskine; Babak Eshrati; Alireza Esteghamati; Kara Estep; Emerito Jose A Faraon; Farshad Farzadfar; Derek F Fay; Valery L Feigin; David T Felson; Seyed-Mohammad Fereshtehnejad; Jefferson G Fernandes; Alize J Ferrari; Christina Fitzmaurice; Abraham D Flaxman; Thomas D Fleming; Nataliya Foigt; Mohammad H Forouzanfar; F Gerry R Fowkes; Urbano Fra Paleo; Richard C Franklin; Thomas Fürst; Belinda Gabbe; Lynne Gaffikin; Fortuné G Gankpé; Johanna M Geleijnse; Bradford D Gessner; Peter Gething; Katherine B Gibney; Maurice Giroud; Giorgia Giussani; Hector Gomez Dantes; Philimon Gona; Diego González-Medina; Richard A Gosselin; Carolyn C Gotay; Atsushi Goto; Hebe N Gouda; Nicholas Graetz; Harish C Gugnani; Rahul Gupta; Rajeev Gupta; Reyna A Gutiérrez; Juanita Haagsma; Nima Hafezi-Nejad; Holly Hagan; Yara A Halasa; Randah R Hamadeh; Hannah Hamavid; Mouhanad Hammami; Jamie Hancock; Graeme J Hankey; Gillian M Hansen; Yuantao Hao; Hilda L Harb; Josep Maria Haro; Rasmus Havmoeller; Simon I Hay; Roderick J Hay; Ileana B Heredia-Pi; Kyle R Heuton; Pouria Heydarpour; Hideki Higashi; Martha Hijar; Hans W Hoek; Howard J Hoffman; H Dean Hosgood; Mazeda Hossain; Peter J Hotez; Damian G Hoy; Mohamed Hsairi; Guoqing Hu; Cheng Huang; John J Huang; Abdullatif Husseini; Chantal Huynh; Marissa L Iannarone; Kim M Iburg; Kaire Innos; Manami Inoue; Farhad Islami; Kathryn H Jacobsen; Deborah L Jarvis; Simerjot K Jassal; Sun Ha Jee; Panniyammakal Jeemon; Paul N Jensen; Vivekanand Jha; Guohong Jiang; Ying Jiang; Jost B Jonas; Knud Juel; Haidong Kan; André Karch; Corine K Karema; Chante Karimkhani; Ganesan Karthikeyan; Nicholas J Kassebaum; Anil Kaul; Norito Kawakami; Konstantin Kazanjan; Andrew H Kemp; Andre P Kengne; Andre Keren; Yousef S Khader; Shams Eldin A Khalifa; Ejaz A Khan; Gulfaraz Khan; Young-Ho Khang; Christian Kieling; Daniel Kim; Sungroul Kim; Yunjin Kim; Yohannes Kinfu; Jonas M Kinge; Miia Kivipelto; Luke D Knibbs; Ann Kristin Knudsen; Yoshihiro Kokubo; Soewarta Kosen; Sanjay Krishnaswami; Barthelemy Kuate Defo; Burcu Kucuk Bicer; Ernst J Kuipers; Chanda Kulkarni; Veena S Kulkarni; G Anil Kumar; Hmwe H Kyu; Taavi Lai; Ratilal Lalloo; Tea Lallukka; Hilton Lam; Qing Lan; Van C Lansingh; Anders Larsson; Alicia E B Lawrynowicz; Janet L Leasher; James Leigh; Ricky Leung; Carly E Levitz; Bin Li; Yichong Li; Yongmei Li; Stephen S Lim; Maggie Lind; Steven E Lipshultz; Shiwei Liu; Yang Liu; Belinda K Lloyd; Katherine T Lofgren; Giancarlo Logroscino; Katharine J Looker; Joannie Lortet-Tieulent; Paulo A Lotufo; Rafael Lozano; Robyn M Lucas; Raimundas Lunevicius; Ronan A Lyons; Stefan Ma; Michael F Macintyre; Mark T Mackay; Marek Majdan; Reza Malekzadeh; Wagner Marcenes; David J Margolis; Christopher Margono; Melvin B Marzan; Joseph R Masci; Mohammad T Mashal; Richard Matzopoulos; Bongani M Mayosi; Tasara T Mazorodze; Neil W Mcgill; John J Mcgrath; Martin Mckee; Abigail Mclain; Peter A Meaney; Catalina Medina; Man Mohan Mehndiratta; Wubegzier Mekonnen; Yohannes A Melaku; Michele Meltzer; Ziad A Memish; George A Mensah; Atte Meretoja; Francis A Mhimbira; Renata Micha; Ted R Miller; Edward J Mills; Philip B Mitchell; Charles N Mock; Norlinah Mohamed Ibrahim; Karzan A Mohammad; Ali H Mokdad; Glen L D Mola; Lorenzo Monasta; Julio C Montañez Hernandez; Marcella Montico; Thomas J Montine; Meghan D Mooney; Ami R Moore; Maziar Moradi-Lakeh; Andrew E Moran; Rintaro Mori; Joanna Moschandreas; Wilkister N Moturi; Madeline L Moyer; Dariush Mozaffarian; William T Msemburi; Ulrich O Mueller; Mitsuru Mukaigawara; Erin C Mullany; Michele E Murdoch; Joseph Murray; Kinnari S Murthy; Mohsen Naghavi; Aliya Naheed; Kovin S Naidoo; Luigi Naldi; Devina Nand; Vinay Nangia; K M Venkat Narayan; Chakib Nejjari; Sudan P Neupane; Charles R Newton; Marie Ng; Frida N Ngalesoni; Grant Nguyen; Muhammad I Nisar; Sandra Nolte; Ole F Norheim; Rosana E Norman; Bo Norrving; Luke Nyakarahuka; In-Hwan Oh; Takayoshi Ohkubo; Summer L Ohno; Bolajoko O Olusanya; John Nelson Opio; Katrina Ortblad; Alberto Ortiz; Amanda W Pain; Jeyaraj D Pandian; Carlo Irwin A Panelo; Christina Papachristou; Eun-Kee Park; Jae-Hyun Park; Scott B Patten; George C Patton; Vinod K Paul; Boris I Pavlin; Neil Pearce; David M Pereira; Rogelio Perez-Padilla; Fernando Perez-Ruiz; Norberto Perico; Aslam Pervaiz; Konrad Pesudovs; Carrie B Peterson; Max Petzold; Michael R Phillips; Bryan K Phillips; David E Phillips; Frédéric B Piel; Dietrich Plass; Dan Poenaru; Suzanne Polinder; Daniel Pope; Svetlana Popova; Richie G Poulton; Farshad Pourmalek; Dorairaj Prabhakaran; Noela M Prasad; Rachel L Pullan; Dima M Qato; D Alex Quistberg; Anwar Rafay; Kazem Rahimi; Sajjad U Rahman; Murugesan Raju; Saleem M Rana; Homie Razavi; K Srinath Reddy; Amany Refaat; Giuseppe Remuzzi; Serge Resnikoff; Antonio L Ribeiro; Lee Richardson; Jan Hendrik Richardus; D Allen Roberts; David Rojas-Rueda; Luca Ronfani; Gregory A Roth; Dietrich Rothenbacher; David H Rothstein; Jane T Rowley; Nobhojit Roy; George M Ruhago; Mohammad Y Saeedi; Sukanta Saha; Mohammad Ali Sahraian; Uchechukwu K A Sampson; Juan R Sanabria; Logan Sandar; Itamar S Santos; Maheswar Satpathy; Monika Sawhney; Peter Scarborough; Ione J Schneider; Ben Schöttker; Austin E Schumacher; David C Schwebel; James G Scott; Soraya Seedat; Sadaf G Sepanlou; Peter T Serina; Edson E Servan-Mori; Katya A Shackelford; Amira Shaheen; Saeid Shahraz; Teresa Shamah Levy; Siyi Shangguan; Jun She; Sara Sheikhbahaei; Peilin Shi; Kenji Shibuya; Yukito Shinohara; Rahman Shiri; Kawkab Shishani; Ivy Shiue; Mark G Shrime; Inga D Sigfusdottir; Donald H Silberberg; Edgar P Simard; Shireen Sindi; Abhishek Singh; Jasvinder A Singh; Lavanya Singh; Vegard Skirbekk; Erica Leigh Slepak; Karen Sliwa; Samir Soneji; Kjetil Søreide; Sergey Soshnikov; Luciano A Sposato; Chandrashekhar T Sreeramareddy; Jeffrey D Stanaway; Vasiliki Stathopoulou; Dan J Stein; Murray B Stein; Caitlyn Steiner; Timothy J Steiner; Antony Stevens; Andrea Stewart; Lars J Stovner; Konstantinos Stroumpoulis; Bruno F Sunguya; Soumya Swaminathan; Mamta Swaroop; Bryan L Sykes; Karen M Tabb; Ken Takahashi; Nikhil Tandon; David Tanne; Marcel Tanner; Mohammad Tavakkoli; Hugh R Taylor; Braden J Te Ao; Fabrizio Tediosi; Awoke M Temesgen; Tara Templin; Margreet Ten Have; Eric Y Tenkorang; Abdullah S Terkawi; Blake Thomson; Andrew L Thorne-Lyman; Amanda G Thrift; George D Thurston; Taavi Tillmann; Marcello Tonelli; Fotis Topouzis; Hideaki Toyoshima; Jefferson Traebert; Bach X Tran; Matias Trillini; Thomas Truelsen; Miltiadis Tsilimbaris; Emin M Tuzcu; Uche S Uchendu; Kingsley N Ukwaja; Eduardo A Undurraga; Selen B Uzun; Wim H Van Brakel; Steven Van De Vijver; Coen H van Gool; Jim Van Os; Tommi J Vasankari; N Venketasubramanian; Francesco S Violante; Vasiliy V Vlassov; Stein Emil Vollset; Gregory R Wagner; Joseph Wagner; Stephen G Waller; Xia Wan; Haidong Wang; Jianli Wang; Linhong Wang; Tati S Warouw; Scott Weichenthal; Elisabete Weiderpass; Robert G Weintraub; Wang Wenzhi; Andrea Werdecker; Ronny Westerman; Harvey A Whiteford; James D Wilkinson; Thomas N Williams; Charles D Wolfe; Timothy M Wolock; Anthony D Woolf; Sarah Wulf; Brittany Wurtz; Gelin Xu; Lijing L Yan; Yuichiro Yano; Pengpeng Ye; Gökalp K Yentür; Paul Yip; Naohiro Yonemoto; Seok-Jun Yoon; Mustafa Z Younis; Chuanhua Yu; Maysaa E Zaki; Yong Zhao; Yingfeng Zheng; David Zonies; Xiaonong Zou; Joshua A Salomon; Alan D Lopez; Theo Vos
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

10.  Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation.

Authors:  Yuko Tanimura; Wataru Aoi; Yoshikazu Takanami; Yukari Kawai; Katsura Mizushima; Yuji Naito; Toshikazu Yoshikawa
Journal:  Physiol Rep       Date:  2016-06
View more
  20 in total

1.  Exercise Training Attenuates Cardiac Vulnerability and Promotes Cardiac Resistance to Isoproterenol-Induced Injury Following Hookah Smoke Inhalation in Male Rats: Role of Klotho and Sirtuins.

Authors:  Samaneh Sadat Alavi; Siyavash Joukar; Farzaneh Rostamzadeh; Hamid Najafipour; Fatemeh Darvishzadeh-Mahani; Abbas Mortezaeizade
Journal:  Cardiovasc Toxicol       Date:  2022-03-22       Impact factor: 3.231

2.  Effect of Exercise Training on 1,25(OH)2D Levels: The FIT-AGEING Randomized Controlled Trial.

Authors:  Alejandro De-la-O; Lucas Jurado-Fasoli; Manuel J Castillo; Ángel Gutiérrez; Francisco J Amaro-Gahete
Journal:  Sports Health       Date:  2021-10-15       Impact factor: 4.355

3.  Commentary: Contextualising Maximal Fat Oxidation During Exercise: Determinants and Normative Values.

Authors:  Francisco J Amaro-Gahete; Guillermo Sanchez-Delgado; Jonatan R Ruiz
Journal:  Front Physiol       Date:  2018-10-18       Impact factor: 4.566

4.  Accuracy and Validity of Resting Energy Expenditure Predictive Equations in Middle-Aged Adults.

Authors:  Francisco J Amaro-Gahete; Lucas Jurado-Fasoli; Alejandro De-la-O; Ángel Gutierrez; Manuel J Castillo; Jonatan R Ruiz
Journal:  Nutrients       Date:  2018-11-02       Impact factor: 5.717

5.  Association between Sleep Quality and Body Composition in Sedentary Middle-Aged Adults.

Authors:  Lucas Jurado-Fasoli; Francisco J Amaro-Gahete; Alejandro De-la-O; Manuel Dote-Montero; Ángel Gutiérrez; Manuel J Castillo
Journal:  Medicina (Kaunas)       Date:  2018-11-19       Impact factor: 2.430

6.  Optimizing Maximal Fat Oxidation Assessment by a Treadmill-Based Graded Exercise Protocol: When Should the Test End?

Authors:  Francisco J Amaro-Gahete; Guillermo Sanchez-Delgado; Jørn W Helge; Jonatan R Ruiz
Journal:  Front Physiol       Date:  2019-07-23       Impact factor: 4.566

7.  Association of basal metabolic rate and fuel oxidation in basal conditions and during exercise, with plasma S-klotho: the FIT-AGEING study.

Authors:  Francisco J Amaro-Gahete; Alejandro De-la-O; Lucas Jurado-Fasoli; Jonatan R Ruiz; Manuel J Castillo
Journal:  Aging (Albany NY)       Date:  2019-08-07       Impact factor: 5.682

8.  Association between sleep quality and time with energy metabolism in sedentary adults.

Authors:  Lucas Jurado-Fasoli; Sol Mochon-Benguigui; Manuel J Castillo; Francisco J Amaro-Gahete
Journal:  Sci Rep       Date:  2020-03-12       Impact factor: 4.379

9.  Interdisciplinary Weight Loss and Lifestyle Intervention for Obstructive Sleep Apnoea in Adults: Rationale, Design and Methodology of the INTERAPNEA Study.

Authors:  Almudena Carneiro-Barrera; Francisco J Amaro-Gahete; Amparo Díaz-Román; Alejandro Guillén-Riquelme; Lucas Jurado-Fasoli; Germán Sáez-Roca; Carlos Martín-Carrasco; Jonatan R Ruiz; Gualberto Buela-Casal
Journal:  Nutrients       Date:  2019-09-15       Impact factor: 5.717

10.  Impact of Using Different Levels of Threshold-Based Artefact Correction on the Quantification of Heart Rate Variability in Three Independent Human Cohorts.

Authors:  Juan M A Alcantara; Abel Plaza-Florido; Francisco J Amaro-Gahete; Francisco M Acosta; Jairo H Migueles; Pablo Molina-Garcia; Jerzy Sacha; Guillermo Sanchez-Delgado; Borja Martinez-Tellez
Journal:  J Clin Med       Date:  2020-01-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.